Qiagen.com

(IN BRIEF) QIAGEN is investing in a new innovation hub in Esplugues de Llobregat, Barcelona, to enhance its QIAstat-Dx syndromic testing platform. Opening in 2026, the 8,000-square-meter site will house operations across research, manufacturing, and regulatory functions, focusing on advancing … Read the full press release →

(IN BRIEF) QIAGEN’s QIAstat-Dx Meningitis/Encephalitis Panel has received FDA clearance, enabling faster and more accurate diagnosis of critical CNS infections like meningitis and encephalitis. This panel, the fourth QIAstat-Dx test approved in the U.S. in 2024, uses real-time PCR to … Read the full press release →

(IN BRIEF) QIAGEN has announced FDA clearance for its QIAstat-Dx Respiratory Panel Mini, marking the third such approval for the QIAstat-Dx system in 2024. Tailored for outpatient settings, this panel quickly detects five common respiratory pathogens—including influenza strains and SARS-CoV-2—enabling … Read the full press release →

(IN BRIEF) QIAGEN Digital Insights has announced an expanded partnership with Neo4j, aiming to enhance biomedical data analysis for the biopharmaceutical industry. This collaboration will integrate Neo4j’s graph database and machine learning capabilities with QIAGEN’s extensive biomedical knowledge base. By … Read the full press release →

(IN BRIEF) QIAGEN has launched an upgraded version of its clinical decision support software, QIAGEN Clinical Insight Interpret (QCI Interpret), tailored for high-throughput next-generation sequencing (NGS) labs. The new release enhances performance metrics like turnaround time and diagnostic yield through … Read the full press release →

(IN BRIEF) QIAGEN, a leading provider of molecular diagnostics and life sciences solutions, is significantly expanding its operations in the Middle East region. In early 2024, the company will open its regional headquarters in Riyadh, Saudi Arabia, to strengthen its … Read the full press release →